- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 207/16
Total number of patents in this class: 1173
10-year publication summary
|
89
|
98
|
84
|
106
|
113
|
103
|
72
|
75
|
58
|
46
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7925 |
27 |
| Bristol-myers Squibb Company | 4898 |
17 |
| Novartis AG | 10849 |
16 |
| Givaudan SA | 1866 |
16 |
| Epics Therapeutics | 18 |
14 |
| Hoffmann-La Roche Inc. | 3418 |
13 |
| Life Technologies Corporation | 3298 |
12 |
| President and Fellows of Harvard College | 5976 |
12 |
| Omeros Corporation | 307 |
12 |
| ThermoLife International, LLC | 126 |
12 |
| Xwpharma Ltd. | 57 |
11 |
| Aichi Steel Corporation | 380 |
10 |
| Biogen MA Inc. | 894 |
10 |
| Cytokinetics, Inc. | 277 |
10 |
| Tokushima University | 213 |
9 |
| Amgen Inc. | 4074 |
8 |
| Abbvie Inc. | 1800 |
8 |
| Astellas Pharma Inc. | 1088 |
8 |
| Enanta Pharmaceuticals, Inc. | 428 |
8 |
| The Regents of the University of California | 19918 |
7 |
| Other owners | 933 |